Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.77 billion, down 1.03% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $6.51 per share and a revenue of $47.31 billion, demonstrating changes of +466.09% and -2.06%, respectively, from the preceding year. Investors should also pay attention to any latest changes in analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.